TIGIT/CD155 axis mediates resistance to immunotherapy in patients with melanoma with the inflamed tumor microenvironment

BACKGROUND: Patients with cancer benefit from treatment with immune checkpoint inhibitors (ICIs), and those with an inflamed tumor microenvironment (TME) and/or high tumor mutation burden (TMB), particularly, tend to respond to ICIs; however, some patients fail, whereas others acquire resistance aft...

Descripción completa

Detalles Bibliográficos
Autores principales: Kawashima, Shusuke, Inozume, Takashi, Kawazu, Masahito, Ueno, Toshihide, Nagasaki, Joji, Tanji, Etsuko, Honobe, Akiko, Ohnuma, Takehiro, Kawamura, Tatsuyoshi, Umeda, Yoshiyasu, Nakamura, Yasuhiro, Kawasaki, Tomonori, Kiniwa, Yukiko, Yamasaki, Osamu, Fukushima, Satoshi, Ikehara, Yuzuru, Mano, Hiroyuki, Suzuki, Yutaka, Nishikawa, Hiroyoshi, Matsue, Hiroyuki, Togashi, Yosuke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Immunotherapy Biomarkers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8603290/
https://www.ncbi.nlm.nih.gov/pubmed/34795004
http://dx.doi.org/10.1136/jitc-2021-003134

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8603290/
https://www.ncbi.nlm.nih.gov/pubmed/34795004
http://dx.doi.org/10.1136/jitc-2021-003134

Ejemplares similares